pemetrexed + gemcitabine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Trial Timeline
Jul 1, 2003 → Mar 1, 2005
NCT ID
NCT00489983About pemetrexed + gemcitabine
pemetrexed + gemcitabine is a phase 2 stage product being developed by Eli Lilly for Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00489983. Target conditions include Non-Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00034489 | Phase 2 | Completed |
| NCT00383331 | Phase 2 | Terminated |
| NCT00394147 | Phase 2 | Terminated |
| NCT00491075 | Phase 2 | Terminated |
| NCT00193414 | Phase 2 | Completed |
| NCT00191503 | Phase 2 | Completed |
| NCT00191347 | Phase 2 | Completed |
| NCT00071136 | Phase 1/2 | Completed |
| NCT00489983 | Phase 2 | Completed |
| NCT00061464 | Phase 2 | Completed |
| NCT00061451 | Phase 2 | Completed |
| NCT00061477 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Small Cell Lung Cancer